Drug Trial Radar · NCT04018027
Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Apr 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
401
Actual
Start
Jun 29, 2019
Primary completion
Apr 1, 2021
Study completion Apr 1, 2021
Sponsor
- Lead sponsor
- Cara Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 12, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, 4-arm, placebo-controlled study to evaluate the efficacy and safety of twice-daily (BID) oral difelikefalin (CR845) in adult subjects with atopic dermatitis (AD) and moderate to severe pruritus.
Conditions
- Pruritus
- Atopic Dermatitis
Interventions
difelikefalin 0.25 mgDrug
Oral difelikefalin 0.25 mg administered twice daily
difelikefalin 0.5 mgDrug
Oral difelikefalin 0.5 mg administered twice daily
difelikefalin 1.0 mgDrug
Oral difelikefalin 1.0 mg administered twice daily
PlaceboDrug
Oral Placebo administered twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in the weekly mean of the daily 24-hour Itch-Numeric Rating Scale (I-NRS) score at Week 12.Time frame: Baseline, Week 12
Locations
40 sites in 2 countries. Site status is shown where the registry gives one.
Cara Therapeutics Study Site
Anniston, Alabama
Cara Therapeutics Study Site
Birmingham, Alabama
Cara Therapeutics Study Site
Scottsdale, Arizona
Cara Therapeutics Study Site
Bryant, Arkansas
Cara Therapeutics Study Site
Fountain Valley, California
Cara Therapeutics Study Site
Lomita, California
Cara Therapeutics Study Site
Cromwell, Connecticut
Cara Therapeutics Study Site
Farmington, Connecticut
Cara Therapeutics Study Site
Aventura, Florida
Cara Therapeutics Study Site 2
Miami, Florida
Cara Therapeutics Study Site
Miami, Florida
Cara Therapeutics Study Site
Miami Lakes, Florida
Cara Therapeutics Study Site
Ocala, Florida
Cara Therapeutics Study Site
Sarasota, Florida
Cara Therapeutics Study Site
Sweetwater, Florida
Cara Therapeutics Study Site
Columbus, Georgia
Cara Therapeutics Study Site
Boise, Idaho
Cara Therapeutics Study Site 2
Boise, Idaho
Cara Therapeutics Study Site
Baton Rouge, Louisiana
Cara Therapeutics Study Site
Metairie, Louisiana
Cara Therapeutics Study Site
New Orleans, Louisiana
Cara Therapeutics Study Site
Brighton, Massachusetts
Cara Therapeutics Study Site 2
Las Vegas, Nevada
Cara Therapeutics Study Site
Berlin, New Jersey
Cara Therapeutics Study Site
Horseheads, New York
Cara Therapeutics Study Site
New York, New York
Cara Therapeutics Study Site
New York, New York
Cara Therapeutics Study Site
Cleveland, Ohio
Cara Therapeutics Study Site
Oklahoma City, Oklahoma
Cara Therapeutics Study Site
Tulsa, Oklahoma
Cara Therapeutics Study Site
Medford, Oregon
Cara Therapeutics Study Site
Rapid City, South Dakota
Cara Therapeutics Study Site 2
Austin, Texas
Cara Therapeutics Study Site
Austin, Texas
Cara Therapeutics Study Site
Cypress, Texas
Cara Therapeutics Study Site
Dallas, Texas
Cara Therapeutics Study Site
Salt Lake City, Utah
Cara Therapeutics Study Site
Richmond, Virginia
Cara Therapeutics Study Site
London, Ontario, Canada
Cara Therapeutics Study Site
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.